$-0.25
(Market cap
$474 Mln
Revenue (TTM)
$35 Mln
P/E Ratio
--
P/B Ratio
2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.4
-
Debt to Equity
0
-
Book Value
$2
-
EPS
$-1
-
Face value
--
-
Shares outstanding
123,025,136
6 Years Aggregate
CFO
$-328.36 Mln
EBITDA
$-444.92 Mln
Net Profit
$-461.17 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
C4 Therapeutics Inc (CCCC)
| 101.6 | 7.2 | 2.9 | 49.2 | 8.1 | -37.9 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
C4 Therapeutics Inc (CCCC)
| -46.9 | -36.0 | -4.2 | -81.7 | -2.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
C4 Therapeutics Inc (CCCC)
|
3.9 | 473.7 | 35.0 | -101.4 | -289.1 | -40.3 | -- | 2.0 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout C4 Therapeutics Inc (CCCC)
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or... IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Read more
-
CEO, President & Director
Mr. Andrew J. Hirsch M.B.A.
-
CEO, President & Director
Mr. Andrew J. Hirsch M.B.A.
-
Headquarters
Watertown, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for C4 Therapeutics Inc (CCCC)
What is the current share price of C4 Therapeutics Inc (CCCC) Today?
The share price of C4 Therapeutics Inc (CCCC) is $3.85 (NASDAQ) as of 28-Aug-2026 16:02 EDT. C4 Therapeutics Inc (CCCC) has given a return of 8.07% in the last 3 years.
What is the current PB & PE ratio of C4 Therapeutics Inc (CCCC)?
Since, TTM earnings of C4 Therapeutics Inc (CCCC) is negative, P/E ratio is not available.
The P/B ratio of C4 Therapeutics Inc (CCCC) is 2.04 times as on 28-Aug-2026, a 62 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-2.12 |
0.87 |
2024 |
-2.41 |
1.18 |
2023 |
-2.18 |
1.18 |
2022 |
-2.25 |
1.00 |
2021 |
-18.61 |
4.01 |
What is the 52 Week High and Low of C4 Therapeutics Inc (CCCC)?
The 52-week high and low of C4 Therapeutics Inc (CCCC) are Rs 5.17 and Rs 1.69 as of 30-Aug-2026.
What is the market cap of C4 Therapeutics Inc (CCCC)?
C4 Therapeutics Inc (CCCC) has a market capitalisation of $ 474 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in C4 Therapeutics Inc (CCCC)?
Before investing in C4 Therapeutics Inc (CCCC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.